Hikari Power Ltd cut its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 8.5% during the 4th quarter, Holdings Channel reports. The firm owned 77,600 shares of the biopharmaceutical company’s stock after selling 7,200 shares during the period. Hikari Power Ltd’s holdings in Bristol-Myers Squibb were worth $4,755,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Blue Chip Partners Inc. grew its stake in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. grew its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 15 shares during the last quarter. Chilton Investment Co. LLC grew its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 26 shares during the last quarter. Keel Point LLC grew its stake in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC lifted its holdings in Bristol-Myers Squibb by 0.4% in the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 49 shares during the period. 69.56% of the stock is currently owned by institutional investors.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 4,000 shares of the stock in a transaction dated Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.

BMY has been the subject of several research analyst reports. Credit Suisse Group restated a “hold” rating and issued a $61.00 price objective (up from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Piper Jaffray Companies restated a “hold” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Leerink Swann raised their price objective on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, January 19th. Finally, Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective for the company. in a report on Thursday, February 8th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $65.58.

Bristol-Myers Squibb Co (NYSE:BMY) opened at $63.87 on Wednesday. Bristol-Myers Squibb Co has a 1-year low of $51.56 and a 1-year high of $66.10. The stock has a market cap of $103,373.98, a P/E ratio of 108.25, a PEG ratio of 1.96 and a beta of 1.09. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The firm had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period last year, the business earned $0.63 earnings per share. The business’s revenue was up 3.9% on a year-over-year basis. sell-side analysts predict that Bristol-Myers Squibb Co will post 3.22 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.51%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 271.19%.

ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co (BMY) Position Lessened by Hikari Power Ltd” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2018/02/14/bristol-myers-squibb-co-bmy-position-lessened-by-hikari-power-ltd.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.